Every year, we check in with our active clients to understand how localisation is working for them and where we can do more. This year, we asked a simple but revealing question: what impact has localisation had on your company? The responses from clients across a range of industries painted a clear picture. Nine out of ten reported a tangible, positive impact on their business.

Here’s what they told us, and what it means in practice.

Localisation as a growth engine

When we combined the responses around reaching new markets (14%), increasing sales or revenue (14%) and reducing time-to-market for products and services (14%), 42% of respondents pointed to localisation as a direct driver of business expansion. That’s a significant proportion, and it reflects a shift in how many organisations are coming to think about multilingual content as a growth enabler.

The connection between localisation and market entry is well established. Consumers are significantly more likely to purchase from a website in their own language and more likely to return. But the link to revenue goes deeper than language preference alone. When your content is culturally adapted 鈥� when it reflects local norms, addresses local concerns and uses familiar frames of reference 鈥� it builds the kind of trust that converts browsers into buyers and first-time customers into loyal ones.

Time-to-market is a less obvious but equally important factor. For businesses launching products or services across multiple regions simultaneously, localisation bottlenecks can delay releases, create inconsistencies between markets and erode competitive advantage. Organisations that integrate localisation early into their development and content workflows consistently find that multilingual content supports rather than slows their launch timelines.

Customer experience and brand: the largest impact area

The biggest single response category was improved customer experience and satisfaction, cited by 27% of respondents. A further 18% said localisation had strengthened their brand globally, making this the combined area where clients felt the most impact overall, at 45%.

It’s worth unpacking why customer experience ranked so highly. Localisation affects every touchpoint a customer has with your brand: your website, your product interface, your support documentation, your marketing communications. When each of these speaks to someone in their own language and cultural context, the cumulative effect is a sense that your brand understands them. That feeling of being understood is one of the most powerful drivers of customer satisfaction and retention.

Brand strength operates on a similar principle, but over a longer horizon. A globally consistent brand that adapts intelligently to local contexts, rather than simply translating its English-language messaging word for word, earns credibility in each market it enters. Inconsistent framing and representation in localised materials and local presence, on the other hand, can quietly undermine the impression of professionalism that global companies work hard to build in their home market. For regulated industries in particular, where trust is foundational, this consistency has direct business value.

Our work with IG Group illustrates this well. By providing consistent, technically accurate multilingual content across regulated markets, localisation contributed directly to stronger confidence in investor-facing and customer-facing communications across eight countries. You can read more in .

The quieter wins: internal communication

One finding that often gets overlooked in conversations about localisation ROI is its internal impact. 5% of respondents highlighted improved internal communication or training as their primary benefit, showing that localisation isn’t exclusively a customer-facing discipline.

For global organisations, the ability to communicate clearly across languages internally is just as important as external messaging. Multilingual training materials ensure that employees in every market receive the same quality of onboarding and development. Internal policies, compliance documentation and operational procedures all carry risk when they’re misunderstood due to language barriers. Investing in the localisation of internal content is, in many cases, an investment in operational consistency and risk management.

What about the 9% who saw no impact?

It would be easy to skip past this, but we think it’s worth acknowledging. A small proportion of respondents said localisation had made no noticeable difference to their business. In our experience, this tends to come down to strategy rather than the work itself.

Localisation delivers the most when it’s planned proactively, aligned to clear business goals and treated as an ongoing programme rather than a reactive, project-by-project exercise. Organisations that localise without first identifying which content is most critical, which markets represent the greatest opportunity or how success will be measured are less likely to see the results they’re hoping for.

If you’re not seeing the impact you expected, it’s worth asking whether localisation is embedded in your wider content and market strategy, or whether it’s still being treated as a procurement task. Our article on centralised versus decentralised localisation strategy is a useful starting point for that conversation.

What this tells us

The results reinforce something we’ve long believed: localisation, done well, has a measurable effect across multiple parts of a business, from revenue and market reach to brand strength, customer loyalty and internal alignment. The range of impact areas also reflects the diversity of our client base, spanning industries with very different content needs and internationalisation goals.

We’re grateful to everyone who took the time to respond this year, and we’ll be drawing on these findings as we continue to develop how we work with you. If any of this resonates or prompts questions about your own localisation programme, we’d love to hear from you at info@stptrans.com.

Would you like to share your thoughts? Join 100+ localisation buyers in this 1-question survey below, and tell us the impact of localisation in your organisation.

Most regulatory submission delays attributed to translation are avoidable. Not because the scientific content was wrong or the regulatory strategy was flawed, but because language was treated as a procurement task and planned for accordingly. The consequence of that framing shows up at the worst possible moment: the submission window opens, the timeline has no flexibility and the bottleneck has been sitting undetected in the documentation workflow for months.

Pharmaceutical regulatory translation covers dossier documentation 鈥� CTD modules, SmPCs, patient information leaflets, pharmacovigilance reports, clinical study reports 鈥� across every market where you intend to seek approval. This article covers where it fails, why those failures are so often invisible until they hit a regulatory deadline and what separates the programmes that manage it well from those that don’t.

The planning assumption that creates the problem

Drug development teams plan meticulously for scientific risk. Clinical endpoints, safety signals, manufacturing scale-up, regulatory feedback 鈥� all modelled, sequenced and resourced well in advance. Translation tends to appear on the project plan late, scoped narrowly and briefed once the scientific content is finalised.

That assumption made more sense before the regulatory environment tightened around it. The gives sponsors a fixed window to submit translated product information in final form during the centralised procedure. Miss that window or submit content that generates questions, and the programme risks being pushed to the next clock-stop cycle.

For teams coordinating submissions across multiple competent authorities simultaneously, the compounding effect is significant. A query from one agency, triggering a document revision, means every translated version across every other market needs updating in parallel. Without structured workflows to manage that, the revision cycle becomes a coordination problem as much as a language problem, and it lands on the desks of regulatory and medical writing teams who were not expecting it.

Clinical trials: where language risk starts

Translation obligations begin well before a dossier is assembled. For patient-reported outcomes, informed consent forms and other patient-facing content, regulators and sponsors frequently require evidence that translated materials convey the original meaning accurately 鈥� not only linguistically, but conceptually. This means back-translation and, for clinical outcome assessments, full linguistic validation, including cognitive debriefing, a step in which a small group of target patients reviews the translated content to confirm it is understood as intended. For a closer look at how these processes work in a clinical trial context, see our clinical trial translation services page.

These processes are time-consuming. Sponsors who discover the requirement during study start-up, with ethics submission timelines already fixed, face a difficult choice between compressing the validation process and delaying the submission. Guidance on patient-reported outcomes is clear that if your programme includes patient-facing content, linguistic validation is expected, and it needs time built around it from the outset of study design.

Marketing authorisation: where pharmaceutical regulatory translation fails

The transition from clinical development to marketing authorisation brings a different set of language challenges. These tend to be structural rather than process-driven, and scale with the complexity of the submission.

Terminology drift across the dossier

A global dossier is dozens of documents, produced by different teams at different stages, often with different reference materials. All of it requires the same controlled terminology across every language: the same compound name, the same indication wording, the same adverse event terminology aligned with .

Without a validated, product-specific termbase maintained throughout the programme, terminology drifts. Not through error 鈥� through the perfectly reasonable independent judgements of translators working without adequate reference materials. Those variations are invisible in any single document. They become visible when a regulator cross-references Module 2 against Module 5, or compares the SmPC against the labelling, and finds them inconsistent.

The resulting clarification requests rarely present as translation problems. They come in as scientific or regulatory queries. The root cause only becomes clear in retrospect, usually after a significant amount of time has been lost.

Version control failures during amendments

Amendment cycles are where multi-market programmes are most vulnerable. Whether it’s a labelling change, a protocol update or a safety amendment, any revision to source content triggers a translation requirement across every active market. In a programme spanning 15 or 20 languages, that’s a significant coordination task.

Without structured version control, markets fall out of sync. The scenario that causes the most disruption is submitting updated content in some markets before others, or submitting content where the translated version reflects an earlier source draft than the one under review. Regulators who catch this do not limit their queries to the translation. They question the integrity of the submission process.

Providers without genuine regulatory depth

There is a practical difference between a translator who is medically qualified and one who understands the regulatory context in which pharmaceutical documents are reviewed. , on summary of product characteristics and FDA regulatory submission standards 鈥� for a pharmaceutical regulatory translator, these are the frameworks that should guide every linguistic decision, not just background knowledge.

A provider without that depth produces translations that are linguistically accurate but regulatorily inconsistent. The compound is named correctly, but the indication is phrased in a way that does not map cleanly to the approved therapeutic area wording. The safety section reads fluently, but uses terminology that diverges from what the agency’s own guidance documents use. These issues typically surface in agency review, at the point where the timeline is least able to absorb them.

Post-approval: the audit trail most teams are unprepared for

Once a product reaches market, pharmacovigilance obligations generate a sustained volume of multilingual documentation, such as PSURs, RMPs, DSURs, individual case safety reports and literature monitoring outputs, that must meet the same standards of accuracy and traceability as submission documentation. The difference is that post-approval documentation is subject to inspection rather than prospective review, which means gaps in process documentation surface during audits rather than at submission.

Regulatory inspections of translation processes are more common than many sponsors anticipate, particularly in post-approval pharmacovigilance audits and GCP inspections of clinical trial documentation. Inspectors ask for documented evidence of how translations were produced: who translated, who reviewed, what reference materials were used, how versions were controlled and how the process was applied consistently across the programme.

ISO 17100-aligned workflows provide that documentation as standard. Many sponsors only discover what their provider’s process documentation actually looks like when an inspector asks for it. Gaps at that point become findings, with the corrective action requirements and re-inspection timelines that follow from them.

Building traceability into translation workflows from the outset 鈥� version records, translator qualifications, review documentation, delivery sign-off 鈥� is far less burdensome to establish at programme start than to reconstruct during an inspection.

Selecting a pharmaceutical translation partner: what to look for

If you’re evaluating providers, whether reconsidering an existing relationship or assessing new ones, these are the areas where the difference between a capable generalist and a genuine pharmaceutical specialist becomes visible.

Termbase and terminology management: Can they build and maintain a product-specific validated termbase? Do they apply it consistently across document types and update it as your programme evolves? Ask to see what that looks like in practice, not just in theory.

Process documentation and ISO alignment: Do they work to ISO 17100? Can they provide documentation of translator qualifications, review stages and version control processes in a format that would satisfy a GCP or pharmacovigilance inspector? Ask for an example before you need it under pressure.

Regulatory familiarity: Ask specific questions: how do they handle MedDRA terminology alignment? What is their approach when the source text is ambiguous and the linguistic choice has regulatory implications? How do they manage EMA linguistic review timelines within the centralised procedure? The answers will tell you quickly whether you are talking to people who truly understand the regulatory environment.

Technology transparency: AI translation has a legitimate role in pharmaceutical programmes for high-volume, lower-risk content with stable phrasing, such as internal training materials or market monitoring. It has no role without significant human review in regulatory submissions, patient-facing materials or safety documentation. A credible provider will be unambiguous about where technology is applied to your content before work begins.

Account management and escalation: In a tight timeline, your language partner needs to be reachable, accountable and able to make decisions quickly. A large provider with rigid workflow hierarchies can be slower in a crisis than a mid-sized specialist, where the person managing your account has the authority to escalate and resolve issues directly.

The internal coordination problem vendors rarely mention

One aspect of pharmaceutical regulatory translation that rarely appears in vendor capability documents is the internal alignment challenge it creates. Regulatory affairs teams, medical writers, localisation managers, QA and procurement all have a stake in how translation is managed, and they frequently disagree on what good looks like and who owns the decision.

That misalignment affects how translation partners get selected and how they’re managed day to day. A QA manager evaluating vendor qualifications is asking different questions than a localisation manager evaluating workflow integration, or a regulatory affairs lead evaluating scientific accuracy. When those perspectives are not reconciled before a vendor relationship begins, selection tends to default to cost and existing relationships rather than regulatory fit, and the gaps only become apparent under submission pressure.

The programmes that manage pharmaceutical regulatory translation most effectively tend to have resolved that internal question first: who is accountable for translation quality, and by what criteria is quality being measured?

What effective planning looks like

The companies that consistently avoid language bottlenecks in their regulatory submissions share a few characteristics. They involve their language partner during study start-up planning, well before submission preparation begins. They maintain validated termbases from early development and update them as the programme progresses. They have structured version control workflows that keep all markets aligned through amendment cycles. And they select providers on the basis of regulatory depth and process transparency, then hold them accountable to it.

Most language-related submission delays come from planning gaps, not from problems that were impossible to anticipate. The documentation volume, the amendment pressure, the audit trail requirements 鈥� none of these are surprises. They are predictable features of global pharmaceutical programmes, and managing them well starts with treating language as a programme-critical function from the outset.

To find out how Sandberg supports regulatory affairs, medical writing and localisation teams from early-phase development through to post-approval obligations, visit our pharmaceutical translation services page.

Clinical trial language requirements are regulatory and ethical standards that ensure all participant-facing and submission documents are translated accurately, clearly and in a way that participants and authorities can fully understand. These requirements focus on informed consent clarity, terminology consistency, cultural adaptation and documented translation workflows.

Clinical trials are becoming increasingly global, with sponsors recruiting participants across multiple countries, languages and healthcare systems. While this diversity strengthens research outcomes, it also introduces a significant challenge: ensuring that every participant, investigator and regulator fully understands trial documentation.

Clinical trial language requirements exist to protect patient safety, preserve data integrity and ensure regulatory compliance. Poor or inconsistent translations can result in participants misunderstanding consent, dosing instructions or safety reporting procedures. In the worst cases, this can compromise both participant welfare and the validity of trial results.

As a result, regulators have placed growing emphasis on language accessibility, traceability and documentation transparency. As clinical trials become more decentralised and patient-centric, translation quality has become a core compliance issue rather than a secondary operational task.

The regulatory foundations behind clinical trial language requirements

Across global markets, regulatory frameworks consistently emphasise one core principle: participants must be able to understand all trial information clearly and in their own language.

require that consent and patient-facing materials be written in non-technical, understandable language. allow member states to determine which languages clinical trial content must be made available in, while strengthening transparency obligations through public reporting systems.

In the UK, recent regulatory reforms have reinforced this focus on accessibility. now places stronger expectations on clarity, plain language communication and timely publication of participant-friendly summaries. These changes reflect a broader shift toward patient-centric research design, where transparency and inclusivity are considered essential to ethical trial conduct.

As a result, translation is no longer treated as a final administrative step. It must now be integrated early into trial planning to meet tighter approval timelines and ensure compliance from the outset.

Where language issues cause delays

1. Ethics committee rejections

Informed consent documentation must meet strict local standards for clarity, readability and terminology. Even small inconsistencies can prompt questions from ethics committees.

When this happens, teams must revise, retranslate and resubmit documents, which can add weeks to approval timelines.

2. Version control complexity

Global trials generate multiple document versions across stakeholders and countries. Without structured workflows, teams may work from outdated files, duplicate efforts or introduce inconsistencies between markets.

Amendments can be particularly disruptive, forcing last-minute updates across multiple languages.

3. Terminology inconsistencies

Clinical terminology must remain consistent across protocols, patient materials and regulatory submissions.

Inconsistent wording can slow regulatory review, increase clarification requests and create risks around participant comprehension.

The ripple effect of language delays

Documentation issues rarely remain isolated, often creating broader operational challenges across the trial ecosystem.

These can include:

• Delayed site activation and recruitment timelines
• Increased workload for regulatory and clinical teams
• Strained sponsor鈥揅RO relationships
• Reduced internal confidence in study readiness

Because language challenges typically emerge late in the process, they can disrupt even well-planned timelines. Preventing these issues therefore requires proactive planning rather than reactive corrections.

Understanding common clinical trial language requirements

Clinical trial language requirements vary by country but typically focus on ensuring participant understanding and regulatory clarity.

Key requirements often include:

• Clear, plain-language informed consent documentation
• Alignment with local ethics committee terminology expectations
• Consistency across protocols, patient materials and submissions
• Back-translation or linguistic validation processes
• Strict version control during amendments

Understanding these requirements early helps prevent avoidable delays later in the study lifecycle and reduces the likelihood of regulatory queries later on.

Which clinical trial documents require translation?

While requirements vary by region, the most commonly translated materials include patient-facing materials, like informed consent forms, participant information sheets, recruitment materials, protocols, regulatory submissions and safety reporting documentation.

Why Quality Assurance and validation are essential

Meeting clinical trial language requirements demands more than accurate translation alone. Structured QA workflows are essential to ensure conceptual consistency and regulatory readiness.

Clinical translation processes often involve multiple review stages designed to confirm accuracy, consistency and clarity. For participant-facing materials, additional validation steps may be used to ensure that translated content is interpreted as intended across different cultural contexts.

Equally important is maintaining a clear audit trail. Regulators expect sponsors to demonstrate how translations were produced, reviewed and approved, reinforcing the need for documented workflows and controlled processes.

The role of cultural adaptation

Imagine a global clinical trial preparing informed consent materials for participants across several countries. The English version explains possible side effects using familiar phrases like 鈥渇lu-like symptoms鈥�, advises patients to contact their primary care doctor if needed and suggests common over-the-counter medicines for relief.

When these materials are translated word-for-word into other languages, they might remain technically correct, but problems quickly appear. In one country, 鈥渇lu-like symptoms鈥� could be interpreted as a serious infectious disease rather than mild discomfort. In another, the idea of contacting a personal doctor causes confusion because patients typically access care directly through hospitals. Some participants also struggle with highly formal medical phrasing that feels dense and difficult to understand.

As ethics committees review the documents, they raise concerns about whether participants would truly comprehend the information. The sponsor must then revise wording, simplify explanations and adapt references to reflect local healthcare realities, which adds extra review cycles and delays study approval.

This is why language requirements extend beyond literal translation. Cultural adaptation plays a vital role in ensuring that clinical information is not only accurate, but meaningful within different social and healthcare contexts.

What effective language planning looks like

Avoiding language-related delays does not typically require complex solutions. In most cases, problems arise from planning gaps rather than technical challenges.

Strong multilingual workflows typically include:

Early integration into study planning: Language requirements are identified during start-up rather than shortly before submission.

Regulatory-aware processes: Local expectations for informed consent and patient materials are considered from the outset.

Structured version control: Clear workflows prevent duplication and confusion across stakeholders.

Consistent terminology management: Approved glossaries ensure alignment across documents and languages.

When these elements are in place, multilingual documentation supports trial timelines rather than disrupting them.

Language as a strategic enabler in clinical trials

Clinical trials are complex, tightly regulated and highly time-sensitive. Every operational element has the potential to either accelerate or delay progress, and multilingual documentation is no exception.

Although translation often operates behind the scenes, its impact on approvals, compliance and participant safety is substantial. When managed effectively, it supports a much smoother process overall.

Many sponsors therefore choose to work with partners providing specialist clinical trial translation services to ensure documentation meets regulatory expectations across all markets. By combining subject-matter expertise with structured workflows, these partners help reduce risk while supporting efficient trial start-up.

Recognising language as an operational factor, rather than simply a procurement task, is often the first step toward fewer delays and more successful global trials.

The future of clinical trial language requirements

As clinical research continues to globalise, clinical trial language requirements are likely to grow in importance. Regulators are placing increasing emphasis on transparency, diversity in participant populations and accessibility of trial information.

Digital technologies and decentralised trial models also introduce new language considerations, including multilingual patient interfaces and remote consent processes.

These trends suggest that high-quality translation will continue evolving from a compliance requirement into a strategic component of ethical and effective clinical research.

EU MDR translation requirements determine which medical device documents must be translated, into which languages, and when those translations must be available. Under the regulation, manufacturers are responsible for ensuring that instructions for use (IFUs), labels, safety information and clinical documentation are provided in the official language or languages required by each EU member state where the device is sold.

The global medical devices market was valued at around and is expected to exceed USD 1000 billion by 2034. Europe remains central to that growth, accounting for more than and ranking as the second-largest market worldwide after the United States.

Since the EU Medical Device Regulation (MDR) became fully applicable in May 2021, language requirements have become clearer, stricter and more closely enforced. By 2026, with the progressive rollout of EUDAMED and increased scrutiny from notified bodies, translation is no longer an administrative afterthought, but a compliance requirement.

If you manufacture or distribute medical devices in Europe, this guide explains what the EU MDR translation requirements mean in practice, and how to stay compliant without slowing down your market entry.

Europe remains a high-value medical device market

Europe鈥檚 medical technology market was estimated at around and has shown steady long-term growth despite economic uncertainty. Healthcare spending across Europe averages around , with close to 8% of this healthcare spending allocated to medical technology, including medical devices.

Innovation remains strong. Of the more than 15,700 medical-related patents filed with the , over 40% originate from EU and EEA countries, with the US and other regions making up the rest.

Germany and the Netherlands consistently rank among the world鈥檚 largest importers of medical devices, making Europe both a centre of innovation and a highly attractive destination for global manufacturers.

The opportunity is clear, but so are the regulatory expectations.

What the EU MDR covers

The governs 鈥渢he placing on the market, making available on the market or putting into service of medical devices for human use and accessories for such devices鈥� within the European Union.

The most notable difference between this regulation and the directives it replaces is the scope. The MDR now covers:

• Medical devices and accessories
• Certain products without an intended medical purpose but with similar risk profiles
• Software used for medical purposes
• Clinical investigations conducted in the EU

It also covers 鈥淒evices with both a medical and a non-medical intended purpose鈥�, but excludes 鈥渋n vitro diagnostic medical devices covered by Regulation (EU) 2017/746鈥� as well as certain medicinal products such as blood, tissue or anything of animal or human origin.

The practical result is more documentation, more oversight and more content that must be translated correctly.

EU MDR language requirements: Clarity, not choice

One of the most important changes introduced by the MDR is how explicitly it addresses language. The previous regulation says that member states 鈥渕ay require鈥� translations to be made into the various languages of the member states, but in MDR, Chapter IV, Article 41, under the heading 鈥淟anguage requirements鈥�, it says:

鈥淎ll documents required pursuant to Articles 38 and 39 shall be drawn up in a language or languages which shall be determined by the Member State concerned.鈥�

Note the subtle but distinct evolution from 鈥渕ay require鈥� to 鈥渟hall be鈥�. In other words, this is not optional, and producers and resellers should not wait for a request to be made.

Article 41 states that all required documentation must be drawn up in the language or languages determined by the member state concerned. In addition, Annex II requires that labels, packaging and instructions for use (IFUs) be provided in the languages accepted in the member states where the device is sold.

For clinical investigations, Annex XV specifies that summaries must be available in an official EU language determined by the relevant member state.

In short, the responsibility now sits firmly with you to:

• Identify language requirements per country
• Prepare compliant translations in advance
• Maintain consistency across all markets

from the European Commission is useful, as it includes tables you can consult to determine which languages you must cover.

Which documents need to be translated under the MDR?

Depending on your device and its classification, the MDR typically requires translation of:

• Labels and packaging (including transport packaging where relevant)
• Instructions for use (IFUs)
• Safety information, warnings and notices
• Declarations of conformity
• Summaries of Safety and Clinical Performance (SSCPs), where applicable
• Clinical investigation documentation and summaries

There is no single EU language rule. Some countries accept English for certain documents, others do not. Multilingual countries may require translations into all official languages.

EUDAMED and terminology consistency in 2026

The has moved from delayed implementation to progressive operational use across its core modules. By May 28, 2026, the first four modules will be mandatory for new devices, and the deadline for legacy devices is November 28.

These modules are:

• Actor registration
• UDI/Devices registration
• Notified Bodies & certificates
• Market surveillance

From a language perspective, this increases the importance of standardised terminology. MDR requires alignment with internationally recognised medical device nomenclature, and inconsistencies between IFUs, labels, technical documentation and database entries are easier to spot.

This makes terminology management, approved glossaries and reusable translation assets essential for long-term compliance.

MDR, Brexit and selling into the EU

The EU MDR does not apply in Great Britain, where medical devices are regulated under the UK MDR 2002 and overseen by the MHRA. However, the EU MDR continues to apply in Northern Ireland.

If you sell into both the UK and EU:

• UK documentation must be in English
• EU documentation must meet member-state-specific language requirements

For UK-based manufacturers exporting to the EU, MDR-compliant translation workflows remain a business necessity.

Why speed and accuracy matter equally

MDR documentation must be available at the point of market entry, which means that translations need to be ready when you submit technical documentation, not afterwards.

At the same time, accuracy is critical. A showed how an incorrect translation of 鈥渘on-modular cemented鈥� as 鈥渨ithout cement鈥� led to dozens of knee implants being applied incorrectly. The issue was not regulation 鈥� it was translation quality.

Poor translation can:

• Delay CE marking
• Trigger regulatory questions
• Increase liability risk
• Compromise patient safety

This is why many manufacturers work with specialist medical device translation services that understand MDR, clinical terminology and regulatory expectations.

Consistency supports compliance and efficiency

As MDR enforcement matures and EUDAMED use increases, consistency across languages becomes easier to audit and harder to overlook.

Using controlled terminology, validated glossaries and translation memory tools helps you:

• Maintain consistency across documents and markets
• Reduce review cycles
• Improve turnaround times
• Lower long-term translation costs

These resources can then be reapplied to subsequent translations, thus saving turnaround time without sacrificing accuracy or introducing inconsistencies. When managed correctly, quality and speed do not have to compete.

Supporting compliance and a healthy bottom line

Europe remains a high-value market for medical devices, but access depends on meeting clear regulatory and linguistic requirements. The MDR aims to reduce ambiguity, protect patients and improve transparency 鈥� and language plays a central role in that goal.

By ensuring your documentation is translated accurately, consistently and in line with member-state requirements, you protect patients, support compliance and keep your products moving to market.

Working with an experienced language partner helps you do all three without unnecessary friction. Read more about our medical translation services here.